Formulation of a prophylactic vaccine against Pseudomonas aeruginosa
Formulation of a prophylactic vaccine against Pseudomonas aeruginosa
批准号:
10481409
负责人:
Aaron C Nagel
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-16 至 2024-02-29
关键词:
AcuteAdjuvantAdultAgeAgingAgonistAnimal ModelAntibiotic ResistanceAntigensBiochemistryBurn injuryCaliberCatheterizationCell membraneCellsCessation of lifeChronicClinicalCritical IllnessDendritic CellsDevelopmentDoseElderlyEmulsionsFormulationGoalsHumanInfectionInjuryInterleukin-17IntubationLipid ALungLung infectionsMicrobial BiofilmsMilitary PersonnelMissionModelingMorbidity - disease rateMusNeedlesNoseOilsOryctolagus cuniculusOutcomePathogenesisPatient CarePatientsPhasePneumoniaPopulationPopulations at RiskPreventive vaccinePrimary InfectionProceduresProteinsPseudomonas aeruginosaPseudomonas aeruginosa infectionPseudomonas aeruginosa pneumoniaPublic HealthRisk FactorsSalesSerotypingSignal TransductionSmall Business Innovation Research GrantStructure of germinal center of lymph nodeTLR4 geneTarget PopulationsTechnologyTeenagersToxic effectToxinType III Secretion System PathwayUrsidae FamilyVaccinatedVaccinationVaccinesVirulentWaterWorkcare costscombat injurycystic fibrosis patientsenterotoxigenic Escherichia colihuman diseasehuman pathogenimprovedlymph nodesmortalitymouse modelmultidrug-resistant Pseudomonas aeruginosanovelpneumonia modelpreventprotective efficacyresponsetherapeutic vaccinevaccine developmentvaccine formulationvaccinologywound
中文摘要
摘要
摘要铜绿假单胞菌是一种重要的机会致病菌,可引起严重感染。
烧伤、严重创伤、肺炎和危重病人需要插管或
导尿术。由于抗生素耐药性,清除PA很困难。多药联用约3.26万例
耐药(MDR)PA每年在住院患者中死亡2700人,患者护理费用7.57亿美元。
此外,PA是囊性纤维化(CF)患者肺部感染的主要原因,其中70%是PA。
被青少年长期殖民的人口。军事人员受到这一事件的严重影响
与战斗相关的伤害中MDR PA的比例。同样重要的是,负面情绪的最大风险因素
与耐多药肺炎相关的结果是高龄。在60岁以后,有一个显著增加
耐多药巴氏杆菌感染的发病率和死亡率。因此,广泛保护性的巴氏杆菌疫苗有很大的市场。
有可能最多接种三种疫苗,为所有人类提供全面保护。数亿美元
疫苗剂量将每年提供,销售额接近50亿美元。虽然已经有巴氏杆菌疫苗在研发中,
没有一家获得许可。我们技术的目标是一种预防性疫苗,防止最初的
PA的定植,不分血清型,以保护脆弱的患者,我们的目标是
对于本研究的成熟成虫,在生物膜形成和宿主适应之前。当第一阶段完成时,
我们将优化疫苗配方,并在小鼠和兔模型上证明了保护效果。
英文摘要
SUMMARY
Pseudomonas aeruginosa (Pa) is an important opportunistic human pathogen that causes severe infections
in patients with burns, severe wounds, pneumonia, and critically ill patients who require intubation or
catheterization. Clearing Pa is difficult due to antibiotic resistance. There are ~32,600 cases of multi-drug
resistant (MDR) Pa in hospitalized patients annually with 2700 deaths and $757 million in patient care costs.
Additionally, Pa is the major cause of pulmonary infections in cystic fibrosis (CF) patients with >70% of this
population being chronically colonized by their teens. Military personnel are gravely impacted by the occurrence
of MDR Pa in combat-related injuries. Equally important is the fact that the biggest risk factor for negative
outcomes associated with infection by MDR Pa is advanced age. After age 60, there is a significant increase in
morbidity and mortality resulting from MDR Pa infection. Thus, a broadly protective Pa vaccine has large market
potential with up to three vaccinations providing complete protection to all humans. Hundreds of millions of
vaccine doses would be given annually, approaching ~$5B in sales. While there are Pa vaccines in development,
none have been licensed. The goal of our technology is a prophylactic vaccine that prevents initial
colonization by Pa, regardless of serotype, to protect vulnerable patients, which we are targeting as
mature adults for this study, prior to biofilm formation and host adaptation. When Phase I is completed,
we will have optimized the vaccine formulation and demonstrated protective efficacy in mice and rabbit models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Formulation of a prophylactic vaccine against Pseudomonas aeruginosa
-
批准号:10592374
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2022
-
负责人:Aaron C Nagel
-
依托单位:
海外基金